Will

Photo: William Stewart Halsted father of modern surgery.

[Will @medtechmd]

$HUMA trial results due June 11. Are they preparing the market?

[Humacyte @humacyte]

Women with AV Access face clear unmet needs.
• 50% fail AVF maturation (vs. 37% in men)1
• 30% use catheter for hemodialysis (vs. 24% in men)1
• 2× higher risk of catheter dysfunction2
• 1 in 2 use infection-prone access – catheters and synthetic grafts1
Be part of the conversation advancing care for women.
VISIT our MEDICAL INFROMATION TEAM at SVS - BOOTH #307

Learn more about Humacyte here: https://t.co/iZqsLFt675

For uses other than the FDA approval in the extremity vascular injury indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

REFERENCES: 1. USRDS 2025 Annual Data. 2. Coker et al., The Journal of Vascular Access, 2018.

Trademarks are property of Humacyte Global, Inc

© 2026 Humacyte Global Inc. All Rights Reserved.
#Humacyte #Innovation #Biotech #VAM2026 #SVS $HUMA #HealthcareInnovation #WomenInMedicine #VascularCare

[Will @medtechmd]

@PersimmonTI Interesting that you have that much confidence!

[Will @medtechmd]

$LULU : A once loved clothing brand, now considered overly expensive. Quite a statement by Jefferies analyst.

[Will @medtechmd]

$ALKS: Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research https://t.co/r3RiZfMPRa

[Will @medtechmd]

$NUVB : Company continues to make progress. Founder & CEO David Hung is a dynamic creator of value.

[Focal One @FocalOneHIFU]

We are excited to showcase @FocalOneHIFU at the 2026 British Association of Urological Surgeons (@BAUSurology) Annual Meeting, a flagship event in the field of urology, highlighting the latest developments in clinical practice, surgical innovation, and research in the UK.

Join us in London from June 15-17 to discover the latest generation Focal One® i system, explore its role in focal therapy, and connect with our team.

Schedule a Hands-On Simulation at our booth: https://t.co/CeUX9kO7r7.

#BAUS2026 | #RoboticSurgery | #MedTech | #HIFU | #Cancer | #ProstateCancer | #Urology

[NeuroPace @NeuroPace]

Always a highlight connecting with the epilepsy community at #ASSFN2026.

Wonderful to see Dr. John Rolston and Dr. Mark Richardson with our own Dr. Martha Morrell. Our Breakfast Symposium on responsive thalamic neuromodulation for drug-resistant epilepsy drew a packed room of clinicians eager to discuss patient selection, emerging data and where the field is heading. The energy and depth of conversation was a testament to how much interest there is in this space. There is clear momentum building around this approach and we are grateful to be part of advancing it.

Thank you to everyone who joined us.

To learn more about the NeuroPace RNS® System, visit https://t.co/D8vjLX05KN.

Safety info: https://t.co/phw9TTn5jG

#NeuroPace #ASSFN #RNSSystem #Epilepsy #NeurologyInnovation

[Will @medtechmd]

$TMDX : The numbers speak for themselves.

[Will @medtechmd]

$TMDX : Responsible for 26% of the organ transplant volume in the USA.

[Will @medtechmd]

SystImmune and $BMY potent dual-targeted EGFRxHER3 bispecific antibody-drug conjugate has now demonstrated clinical benefit in three Phase 3 trials in China, underscoring its broad therapeutic potential in multiple tumor types https://t.co/DOxh80vm0S

[Will @medtechmd]

With regard to cancer signal attributed to $ABBX molecule; those old enough to remember secondary primary malignancy potential associated with Lenalidomide (Revlimid) use. The debate and overhang persisted for quite sometime. Difficult to dispel that association with investors.

[Will @medtechmd]

We are very constructive on the setup for $LNTH in '26-27 and continue to see shares as undervalued; Buy. Management “not commenting on take-out headlines.”

[Will @medtechmd]

$PRAX trial fails in Focal Epilepsy. $XENE looking for FDA approval year end 2026,

[Will @medtechmd]

“Waterfall showed tumor shrinkage in 77% of evaluable pts across tumor types/dosages”. $KURA

[Will @medtechmd]

@seedy19tron Interested to join.

[Lawrence McDonald @Convertbond]

It’s not where you start, it’s where you finish. Pretty good start here as well.

[Will @medtechmd]

$NPCE to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting | NeuroPace, Inc. https://t.co/bKU7ZMqjuU

[Will @medtechmd]

$NPCE Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care | NeuroPace, Inc. https://t.co/UVY0ThqdaD

[Will @medtechmd]

$EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy | Focal One® https://t.co/f9XA66uMs9

[NeuroPace @NeuroPace]

We are on the floor at ASSFN! Stop by Booth #107 to connect with the clinical team, and learn more about the RNS® System for drug-resistant focal epilepsy.



See you there!

Rx Only. The RNS® System is an adjunctive therapy for adults with refractory, partial onset seizures with no more than 2 epileptogenic foci. See important safety information at https://t.co/phw9TTn5jG